DDInter1104 DDInter1082
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Lurasidone {u} (Compound) resembles {v} (Compound) Ziprasidone
Lurasidone {u} (Compound) binds {v} (Gene) DRD2
Lurasidone {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Lurasidone {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Lurasidone {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Lurasidone (Compound) resembles Ziprasidone (Compound)
Lurasidone (Compound) binds DRD2 (Gene)
Lurasidone (Compound) causes Hepatobiliary disease (Side Effect)
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Lurasidone may lead to a major life threatening interaction when taken with Crizotinib
Lurasidone may lead to a major life threatening interaction when taken with Clarithromycin